Medicare to cover PFAS blood tests free for seniors starting 2028

What it does

This bill amends Medicare to cover PFAS blood tests for seniors at no cost starting January 1, 2028. PFAS (per- and polyfluoroalkyl substances) are industrial chemicals linked to health risks; the bill requires Medicare to pay 100% of the cost of physician-ordered PFAS tests, treating them as preventive services under the same fee schedule as other screening tests.

Why we flagged it

The bill's sole operative mechanism is adding a specific health screening test to Medicare's covered preventive services with full cost coverage. It is a straightforward expansion of an existing benefit category.

What the text implies

• The January 1, 2028 effective date creates a 3-year delay before coverage begins, potentially allowing time for clinical evidence to accumulate or for regulatory guidance on PFAS testing standards to develop.
• The bill ties PFAS test reimbursement to the existing fee schedule for 'screening and preventive services' (Section 1861(ww)(2)), meaning Medicare's payment rate will follow whatever rates are established for comparable preventive tests—this avoids setting a new rate but leaves actual cost exposure dependent on how CMS prices the test.
• No explicit requirement that the PFAS test be FDA-approved or meet specific clinical standards; coverage depends on physician order, which may create variation in testing protocols across providers.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Seniors gain access to a health screening test at no out-of-pocket cost, removing a financial barrier to detecting exposure to chemicals linked to serious health conditions. The bill expands preventive care coverage without restricting existing benefits or imposing new limitations on Medicare beneficiaries.

Who stands to gain

• Clinical laboratories offering PFAS blood testing
• Diagnostic testing companies
• Healthcare providers billing for PFAS screening

Named in the bill

Medicare, Social Security Act, Section 1861, Section 1833, CMS (Centers for Medicare & Medicaid Services), PFAS (per- and polyfluoroalkyl substances)

Where it stands

2 cosponsors: 1 Democrats, 1 Republicans.

• Sep 26, 2025 — Introduced · Congress.gov: “Introduced in House”
• Sep 26, 2025 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 2 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $820,000 in lobbying spend. A filing names 10 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Debbie Dingell, the sponsor, reported $747,585 in PAC receipts in the 2026 cycle. $2,500 of that came from 1 PAC tied to these lobbying clients.

• Quest Diagnostics Incorporated — $820,000 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.